Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Exagen Inc.

NASDAQ: XGN · Industrial Applications and Services · 8 alerts · CIK 1274737

Share price
$3.77Close, Nov 16
Market cap
$96.2M
Shares outstanding
25.51MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Exagen Inc. filings on SEC EDGAR ↗

9:43 PM ET Form 4
Insider Selling

Exagen Insider Jorey Chernett Sells $746K of Stock

Jorey Chernett sold 167,504 shares of Exagen Inc. at $4.08 to $4.65 a share (average $4.45) in 2 transactions, worth $746K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 2,529,436 (-2.2%).

Value
$746K
Shares
167,504
Average price
$4.45
Holding change
-2.2%
Trade date
Nov 12, 2026 to Nov 13, 2026
8:16 AM ET Form 4
Insider Buying

Exagen Insider Jorey Chernett Buys $373K of Stock

Jorey Chernett bought 71,315 shares of Exagen Inc. at $5.23 a share, worth $373K in total on Nov 11, 2026. Shares held after the trade: 2,696,940 (+2.7%).

Value
$373K
Shares
71,315
Price
$5.23
Holding change
+2.7%
Trade date
Nov 11, 2026
8:05 PM ET Form 4
Insider Buying

Exagen Insider Jorey Chernett Buys $91.2K of Stock

Jorey Chernett bought 15,585 shares of Exagen Inc. at $5.26 to $6.35 a share (average $5.85) in 2 transactions, worth $91.2K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,625,625 (+0.3%).

Value
$91.2K
Shares
15,585
Average price
$5.85
Holding change
+0.3%
Trade date
Nov 9, 2026 to Nov 10, 2026
8:05 PM ET Form 4
Insider Selling

Exagen Insider Jorey Chernett Sells $69.2K of Stock

Jorey Chernett sold 11,265 shares of Exagen Inc. at $6.14 a share, worth $69.2K in total on Nov 6, 2026. Shares held after the trade: 2,610,040 (-0.4%).

Value
$69.2K
Shares
11,265
Price
$6.14
Holding change
-0.4%
Trade date
Nov 6, 2026
9:02 AM ET 10-Q
Financial Results

Exagen Q3 2026 Results: Net Loss of $6.34M, Loss Narrows

Exagen Inc. reported revenue of $18.4 million for Q3 2026, a 6.8% increase year-over-year, while narrowing its net loss to $6.3 million compared to $7.1 million in Q3 2025. The company strengthened its capital position through $6.4 million in net proceeds from an at-the-market (ATM) equity offering during the quarter.

Key figure
Net loss $6.34M
7:33 AM ET 8-K
Financial Results

Exagen Financial Results

Exagen Inc. reported third quarter 2026 revenue of $18.4 million, a 7% increase year-over-year, driven by growth in test volume and average selling price. The company reduced its net loss to $6.3 million for the quarter and reiterated its full-year 2026 revenue guidance of $72 million to $75 million.

Term
Q3 2026

“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”

John Aballi, President and Chief Executive Officer of Exagen
8:00 AM ET Form 4
Insider Buying

Exagen Insider Jorey Chernett Buys $104K of Stock

Jorey Chernett bought 14,000 shares of Exagen Inc. at $7.46 a share, worth $104K in total on Oct 19, 2026. Shares held after the trade: 2,618,540 (+0.5%).

Value
$104K
Shares
14,000
Price
$7.46
Holding change
+0.5%
Trade date
Oct 19, 2026
4:52 PM ET Form 4
Insider Selling

Exagen President and CEO John Aballi Sells $270K of Stock

John Aballi, President and CEO, sold 34,294 shares of Exagen Inc. at $7.87 a share, worth $270K in total on Oct 16, 2026. Shares held after the trade: 805,540 (-4.1%).

Value
$270K
Shares
34,294
Price
$7.87
Role
President and CEO
Holding change
-4.1%
Trade date
Oct 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.